A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours

Autor: Aya El Helali, Ruth Plummer, Gordon C. Jayson, Vicky M. Coyle, Yvette Drew, Nerissa Mescallado, Noor Harris, Andrew R. Clamp, Janine McCann, Helen Swaisland, Richard D. Kennedy, Aaron N. Cranston, Richard H. Wilson

Publikováno v: El Helali, A, Plummer, R, Jayson, G C, Coyle, V M, Drew, Y, Mescallado, N, Harris, N, Clamp, A R, McCann, J, Swaisland, H, Kennedy, R D, Cranston, A N & Wilson, R H 2022, ' A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours ', British Journal of Cancer . https://doi.org/10.1038/s41416-022-01780-z

Background We aimed to assess the safety, tolerability and pharmacokinetics of a novel anti-angiogenic peptide. Methods We used an open-label, multicentre, dose-escalation Phase I trial design in patients with solid tumours. ALM201 was administered s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::743ea9c16821a65b88f7554b9f484464
https://eprints.gla.ac.uk/271930/1/271930.pdf

In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450

Autor: Venkatesh Pilla Reddy, Helen Swaisland, Alex McCormick, Graeme Scarfe, Maria Learoyd

1. In vitro studies were conducted to evaluate potential inhibitory and inductive effects of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, on cytochrome P450 (CYP) enzymes. Inhibitory effects were determined in human liver microsomes (H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30133b314b68a9dbfcd7db60bd7db7a1

In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib

Autor: Alex McCormick, Helen Swaisland

Publikováno v: Xenobiotica; the fate of foreign compounds in biological systems. 47(10)

1. In vitro assessments were conducted to examine interactions between olaparib (a potent oral inhibitor of poly[ADP-ribose] polymerase) and drug transporters.2. Olaparib showed inhibition of the hepatic drug uptake transporters OATP1B1 (IC50 values

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f86265ff9648266150dc74c75a64f63
https://pubmed.ncbi.nlm.nih.gov/27684210

Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies

Autor: Sally Garnett, Anitra Fielding, Helen Swaisland, Karen So, Ruth Plummer, Wendy Bannister, Marc-Antoine Fabre, Corina Dota

Publikováno v: Cancer chemotherapy and pharmacology. 78(4)

Some therapeutic agents in oncology can be causally associated with specific cardiovascular events including QT/QTc interval prolongation. We investigated the effect of multiple dosing of the oral poly (ADP-ribose)-polymerase (PARP) inhibitor, olapar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::050280776b1f52b126972ec941247ac4
https://pubmed.ncbi.nlm.nih.gov/27553432

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies

Autor: L Rhoda Molife, Ruth Plummer, Dorte Nielsen, Sylvie Rottey, Anitra Fielding, Wendy Bannister, Guy Jerusalem, Helen Swaisland, Carla M.L. van Herpen, Karen So, Morten Mau-Sørensen, Judith de Vos-Geelen, Christian Rolfo, Rebecca Kristeleit, Karin Leunen, Luc Dirix, Henk M.W. Verheul, Patricia M. M. B. Soetekouw

Publikováno v: Clinical Therapeutics, 38, 10, pp. 2286-2299
Dirix, L, Swaisland, H, Verheul, H M W, Rottey, S, Leunen, K, Jerusalem, G, Rolfo, C, Nielsen, D, Molife, L R, Kristeleit, R, de Vos-Geelen, J, Mau-Sorensen, M, Soetekouw, P, van Herpen, C, Fielding, A, So, K, Bannister, W & Plummer, R 2016, ' Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies ', Clinical Therapeutics, vol. 38, no. 10, pp. 2286-2299 . https://doi.org/10.1016/j.clinthera.2016.08.010
Clinical Therapeutics, 38, 2286-2299
Clinical therapeutics
Clinical Therapeutics, 38(10), 2286-2299. Excerpta Medica

Item does not contain fulltext PURPOSE: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrated efficacy in patients with BRCA-mutated ovarian cancer, is mediated by cytochrome P450 (CYP) enzymes (predom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6843893bce29d8f4df1d533e6f57d2c
https://hdl.handle.net/2066/172406